Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

DFA-02 in Patients Undergoing Colorectal Surgery

This study has been completed.
Duke Clinical Research Institute
Information provided by (Responsible Party):
Dr. Reddy's Laboratories Limited Identifier:
First received: December 15, 2011
Last updated: August 15, 2014
Last verified: August 2014
This is a randomized, double-blind, placebo controlled, safety, tolerability, and pharmacokinetic dose escalation Phase II study of DFA-02 in patients undergoing colorectal surgery to evaluate the safety, tolerability and pharmacokinetics of DFA-02.

Condition Intervention Phase
Surgical Site Infection
Drug: DFA-02
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo Controlled, Safety, Tolerability, and Pharmacokinetic Dose Escalation Study of DFA-02 in Patients Undergoing Colorectal Surgery

Further study details as provided by Dr. Reddy's Laboratories Limited:

Primary Outcome Measures:
  • Number of Patients With Adverse Events, Laboratory, Physical Examination Changes [ Time Frame: Baseline up to Day 30 ]
    Safety and tolerability measured by number of patients with adverse events or changes in laboratory or physical examination findings from baseline (DFA-02 application during surgery on Day 1) to 30 days after surgery.

  • Area Under Curve (AUC) [ Time Frame: 1, 6, 24, 48 96 hours post-dose ]
    Area under the curve (AUC) of plasma gentamicin and vancomycin levels using sparse sampling from baseline (DFA-02 application during surgery on Day 1) to 4 days after surgery

Secondary Outcome Measures:
  • Maximal Plasma Concentration (Cmax) [ Time Frame: 1, 6, 24, 48, 96 hours post-dose ]
    Maximal plasma concentration (Cmax)of gentamicin and vancomycin using sparse sampling from baseline (DFA-02 application during surgery on Day 1) to 4 days after surgery

  • Renal Function [ Time Frame: Baseline up to Day 14 ]
    Changes in serum creatinine from surgery on Day 1 until 14 days after surgery

  • Antibiotic Resistance [ Time Frame: Baseline up to Day 5 ]
    Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus presence at surgery on Day 1 and 5 days after surgery

  • Incidence of Surgical Site Infection [ Time Frame: Up to 30 Days After Surgery ]
    The incidence of probable or definite surgical site infection as determined by the Investigator.

Enrollment: 30
Study Start Date: February 2012
Study Completion Date: June 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DFA-02
Progressive cohorts of 10 subjects (8 active, 2 placebo) receiving 10, 20 , 30 or 40 mL of DFA-02 or matching placebo.
Drug: DFA-02
Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
Placebo Comparator: DFA-02 placebo Drug: Placebo
DFA-02 placebo

Detailed Description:
Despite antibiotic prophylaxis and improvements in surgical techniques, surgical site infections (SSI) still occur. DFA-02 is a novel bioresorbable modified release gel containing both gentamicin and vancomycin to be applied during surgical incision closure for the prevention of surgical site infections (SSIs) in patients undergoing colorectal surgery.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males and females 18 years of age or older;
  2. If female, the patient must be:

    • postmenopausal (if amenorrheic for < 1 year, postmenopausal status must be confirmed by an elevated follicle stimulating hormone [FSH] level > 30 mIU/mL; if amenorrheic for > 1 year, FSH level not required);
    • surgically sterilized (does not have a uterus or has had bilateral tubal ligation); or
    • if of child-bearing potential, she must have a negative serum pregnancy test on entry in the study, and agree to use adequate birth control during the study and for 30 days after the administration of study agent. Medically acceptable contraceptives include: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD);
  3. BMI 25-40, inclusive;
  4. Scheduled to undergo nonemergent colorectal surgery involving a laparotomy incision of 7 cm or greater (hand-assisted laparoscopic surgery is allowed). List of eligible procedures: left, right or transverse colectomy, segmental/sleeve left colon resection, total abdominal colectomy with ileorectal anastomosis, total abdominal colectomy with ileostomy, total abdominal proctocolectomy, low anterior resection, sigmoid resection, non-emergent Hartmann's procedure, colotomy with polypectomy distal to hepatic flexure, colostomy takedown through laparotomy (not peristomal) incision, ileo-pouch anal anastomosis, abdominal perineal resection of the rectum;
  5. Willing and able to give informed consent;
  6. Available for evaluation from baseline until final evaluation at 30 days post surgery.

Exclusion Criteria:

  1. Known history of hypersensitivity to gentamicin or vancomycin, other aminoglycoside antibiotics or the excipients of the study products (soy bean products or sesame oil);
  2. Emergency surgery (urgent surgery is allowed if informed consent is obtained and the study procedures can be performed);
  3. Significant concomitant surgical procedure (Note: concomitant appendectomy, cholecystectomy, oophorectomy, and liver biopsy/wedge resection are allowed);
  4. Prior laparotomy within the last 60 days of this planned procedure;
  5. Planned second laparotomy or colorectal surgical procedure (e.g. colostomy or ileostomy takedown) within 30 days of this planned first procedure;
  6. Expectation that a surgical drain will be placed;
  7. Preoperative sepsis, severe sepsis, or septic shock;
  8. Abdominal wall infection/surgical site infection from previous laparotomy/laparoscopy or for any reason;
  9. Active systemic infection or systemic (oral or intravenous) antibiotic therapy within the 1 week prior to the date of surgery other than specified preoperative antimicrobial prophylaxis (Note: single dose antibiotic therapy for dental or other minor procedures is allowed as is the use of oral non-absorbable antibiotics for preoperative bowel decontamination);
  10. Requirement for gentamicin or vancomycin preoperative antimicrobial prophylaxis (Note: systemic antibiotic therapy within 72 hours after surgery with gentamicin or vancomycin must be avoided and any systemic antibiotic therapy during that time should be discussed with the Coordinating Center PI or Medical Monitor);
  11. Requirement for concomitant use or use during the 30 days prior to Day 1 of any prescription or OTC drug that would interfere with the study or place the patient at undue risk. Concurrent systemic or topical use of other potentially neurotoxic, nephrotoxic, and/or ototoxic drugs, such as gentamicin, cisplatin, cephaloridine, kanamycin, amikacin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, ethacrynic acid, furosemide, and viomycin, should be avoided;
  12. Preoperative evaluation suggests an intra-abdominal process that might preclude full closure of the skin;
  13. Ongoing treatment (e.g. chemotherapy, radiation) for non-colorectal cancer;
  14. History of significant drug or alcohol abuse within the past year;
  15. Serum Creatinine > 1.3 mg/dL
  16. Serum Bilirubin > 2.5 times upper limit of normal;
  17. History of uncontrolled diabetes mellitus (controlled diabetic patients whose hemoglobin A1c is ≤ 9.0% may be included);
  18. Patients who are immunocompromised including but not limited to systemic corticosteroid use or chemotherapy/radiation during the 30 days prior to surgery, organ transplantation, or HIV infection (Note: inhaled corticosteroids are not exclusionary and single dose use of corticosteroids to prevent PONV is allowed.);
  19. Any clinically meaningful hearing loss (from Medical History);
  20. Clinically exclusionary results on clinical laboratory, ECG, or physical examination including but not limited to positive hepatitis B or C or HIV;
  21. Pregnant or lactating, or if of childbearing potential not practicing a birth control method with a high degree of reliability;
  22. Refusal to accept medically indicated blood products;
  23. Participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of investigational drug or device within 60 days is anticipated;
  24. Patients with anterior abdominal wall mesh that is not planned to be completely removed during the planned procedure;
  25. Unable to participate in the study for any reason in the opinion of the Principal Investigator;
  26. Postsurgical life expectancy of less than 30 days, in the Investigator's or Sponsor's opinion;
  27. Expected discharge from the hospital less than 3 days after surgery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01496352

United States, Alabama
Florence, Alabama, United States
United States, Florida
Tampa, Florida, United States
United States, Ohio
Columbus, Ohio, United States
United States, Texas
Bellaire, Texas, United States
Temple, Texas, United States
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Duke Clinical Research Institute
Study Director: Kent Allenby, MD Dr. Reddy's Laboratories
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Reddy's Laboratories Limited Identifier: NCT01496352     History of Changes
Other Study ID Numbers: DFA-02-CD-002
Study First Received: December 15, 2011
Results First Received: August 15, 2014
Last Updated: August 15, 2014

Keywords provided by Dr. Reddy's Laboratories Limited:
Surgical site infection
Colorectal surgery

Additional relevant MeSH terms:
Surgical Wound Infection
Wound Infection
Postoperative Complications
Pathologic Processes processed this record on April 27, 2017